Bioanalysis · 2015
DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application.
Оценочное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Antunes Marina Venzon, Raymundo Suziane, Wagner Sandrine Comparsi, Mattevi Vanessa Suñé, Vieira Natalia, Leite Renata, Reginato Fabiola, Capra Marcelo Zanella, Fogliatto Laura, Linden Rafael
Аннотация
BACKGROUND: Imatinib (IM) is widely used in treatment of chronic myeloid leukemia with target trough plasma concentrations above 1000 ng ml(-1). DBS can increase access to IM therapeutic drug monitoring.
RESULTS: IM was measured in the range 50-4000 ng ml(-1) by UHPLC-MS/MS using one 6 mm DBS in a fully validated method. IM was stable at DBS maintained at 40°C for 36 days. Plasma and DBS concentrations were highly correlated (r > 0.96). The use of a IM concentration target of 765 ng ml(-1) in DBS identified 93% of patients with plasma concentration below 1000 ng ml(-1).
CONCLUSION: IM can be measured in DBS using UHPLC-MS/MS with results comparable to those obtained in blood plasma.
RESULTS: IM was measured in the range 50-4000 ng ml(-1) by UHPLC-MS/MS using one 6 mm DBS in a fully validated method. IM was stable at DBS maintained at 40°C for 36 days. Plasma and DBS concentrations were highly correlated (r > 0.96). The use of a IM concentration target of 765 ng ml(-1) in DBS identified 93% of patients with plasma concentration below 1000 ng ml(-1).
CONCLUSION: IM can be measured in DBS using UHPLC-MS/MS with results comparable to those obtained in blood plasma.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overChildChromatography, High Pressure LiquidDried Blood Spot TestingDrug MonitoringFemaleHematocritHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPatient Acceptance of Health CareReproducibility of ResultsSurveys and QuestionnairesTandem Mass SpectrometryYoung Adult